Ambrx, a San Diego-Shanghai Biotech, Files for $100 Million US IPO
June 07, 2021 at 05:41 AM EDT
Ambrx, a San Diego clinical-stage biotech with operations in Shanghai , filed for a US IPO that is expected to raise $100 million. Founded in 2003, Ambrx develops antibody-drug conjugates and bispecifics for unmet oncology needs. It builds engineered precision biologics by incorporating synthetic amino acids (SAAs) into proteins within living cells, a technology that offers better efficacy and safety, according to the company. Its lead drug, an ADC candidate, is being tested in a China Phase II/III trial for HER2-positive metastatic breast cancer led by a China partner, NovoCodex Biopharma. More details.... Share this with colleagues: // //